Year: 2006
Type: article
Abstract: National blood donor screening for West Nile virus (WNV) RNA using minipool nucleic acid amplification testing (MP-NAT) was implemented in the United States in July 2003. We compiled national NAT yield data and performed WNV immunoglobulin M (IgM) testing in 1 WNV-epidemic region (North Dakota). State-specific MP-NAT yield, antibody seroprevalence, and the average time RNA is detectable by MP-NAT were used to estimate incident infections in 2003. WNV donor screening yielded 944 confirmed viremic donors. MP-NAT yield peaked in August with >0.5% of donations positive for WNV RNA in 4 states. Peak IgM seroprevalence for North Dakota was 5.2% in late September. The average time viremia is detectable by MP-NAT was 6.9 days (95% confidence interval [CI] 3.0-10.7). An estimated 735,000 (95% CI 322,000-1,147,000) infections occurred in 2003, with 256 (95% CI 112-401) infections per neuroinvasive case. In addition to preventing transfusion-transmitted WNV infection, donor screening can serve as a tool to monitor seasonal incidence in the general population.
Source: Emerging infectious diseases
Institutions: University of California, San Francisco, Blood Systems Research Institute, Westat (United States), American Red Cross, University of British Columbia, District of Columbia Water and Sewer Authority, Centers for Disease Control and Prevention, National Institutes of Health, National Heart, Lung, and Blood Institute
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G1143517056, EPIDEMIOLOGY OF HUMAN RETROVIRUSES IN BLOOD DONORS, EPIDEMIOLOGIC STUDIES OF HUMAN RETROVIRUSES IN BLOOD, EPIDEMIOLOGIC STUDY OF HUMAN RETROVIRUSES IN BLOOD DONOR, EPIDEMIOLOGY OF HUMAN RETROVIRUSES IN BLOOD DONORS, G555899134, G6599219787, EPIDEMIOLOGY OF HUMAN RETROVIRUSES IN BLOOD DONORS, G746114387, RETROVIRUS EPIDEMIOLOGY DONOR STUDY (REDS) BLOOD CENTER, G9205973, G963945440
OpenAlex ID: W2033969877
